Clinical and Laboratory ObservationsAcute Pain Relief After Mantram Meditation in Children With Neuroblastoma Undergoing Anti-GD2 Monoclonal Antibody TherapyAhmed, Mahiuddin PhD; Modak, Shakeel MD; Sequeira, Sonia PhDAuthor Information *Department of Pediatrics †Office of Clinical Research, Memorial Sloan-Kettering Cancer Center, New York, NY The authors declare no conflict of interest. Reprints: Sonia Sequeira, PhD, Office of Clinical Research, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 (e-mail: email@example.com). Received March 21, 2013 Accepted August 20, 2013 Journal of Pediatric Hematology/Oncology: March 2014 - Volume 36 - Issue 2 - p 152-155 doi: 10.1097/MPH.0000000000000024 Buy Metrics Abstract Nonpharmacologic, mind-body interventions are used to reduce anxiety in pediatric patients. Anti-ganglioside GD2 monoclonal antibody (anti-GD2 MoAb 3F8) therapy is the standard of care for high-risk neuroblastoma and pain is its major side effect. We performed a retrospective analysis of children undergoing anti-GD2 MoAb 3F8 treatment who received guided meditation. Meditation involved concentrating on the repetition of rhythmic, melodic sounds purported to slow breathing and induce a relaxation response. A total of 71% patients completed a session at first (n=19) or second attempt (n=5). Patients received fewer analgesic doses to manage anti-GD2 MoAb 3F8-induced pain when participating in meditation (n=17, mean=−0.4 dose, P<0.01). Mantram meditation is a feasible outpatient intervention associated with reduced analgesic requirements. Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.